Latest news for Adicet Bio (NASDAQ:ACET) Stock

Adicet Bio

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

analyst ratings image

News

Downgrades

Markets

Analyst Ratings

Trading Ideas

ACET

ANIP

RLAY

SUPN

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday

IN8bio’s Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data 

Biotech

Penny Stocks

General

INAB

IPSC

IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these cells to effectively target and eliminate cancer cells in both solid and hematological tumors.

IN8bio&#39;s Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data

Small Cap

Intraday Update

Movers

ACCD

ACMR

AIMD

BETS

BOWL

CENX

CUTR

DECA

GOEV

GRFS

GRTX

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

ILMN

JBLU

JNPR

JWEL

KITT

KORE

LDTC

Morgan Stanley Capital Protected Notes for S&P 500 Index

NEOG

NEXI

SNTG

TCJH

TLRY

URBN

VIRI

YCBD

ZCAR

PTHR

Shares of JetBlue Airways Corporation (NASDAQ: JBLU) fell sharply during Tuesday’s session.

Why JetBlue Airways Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Adicet Bio Inc

Wedbush analyst Robert Driscoll reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Outperform and maintains $5 price target.

Price Target

Reiteration

Wedbush Reiterates Outperform on Adicet Bio, Maintains $5 Price Target

HC Wainwright &amp; Co. analyst Edward White reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Neutral.

HC Wainwright & Co. Reiterates Neutral on Adicet Bio

ADI-001 demonstrated robust tissue trafficking resulting in high levels of ADI-001, significant chimeric antigen receptor (CAR) T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue.&nbsp;

Health Care

Adicet Bio Announced ADI-001 Clinical Biomarker Data From The Phase 1 GLEAN Trial Which Further Reinforces The Potential Of ADI-001 As Allogeneic Cell Therapy For Autoimmune Diseases

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58a5e02a43eaaa00018d939e/edward-white">HC Wainwright &amp; Co. analyst Edward White</a> downgraded the rating for Adicet Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Buy to Neutral. Adicet Bio shares fell 3.4% to close at $1.43 on Tuesday. <a href="https://www.benzinga.com/quote/DACETPZ/analyst-ratings">See how other analysts </a><a href="https://www.benzinga.com/quote/ACET/analyst-ratings">view </a><a href="https://www.benzinga.com/quote/DACETPZ/analyst-ratings">this stock</a>.</li>
<li>B of A Securities analyst Graham Perry downgraded Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from Buy to Neutral and lowered the price target from $135 to $130. Novartis shares fell 0.2% to close at $116.99 on Tuesday. <a href="https://www.benzinga.com/quote/NVS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/topic/david-amsellem">Piper Sandler analyst David Amsellem</a> downgraded the rating for Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) from Overweight to Neutral and cut the price target from $41 to $36. Supernus Pharmaceuticals shares fell 1.2% to close at $33.49 on Tuesday. <a href="https://www.benzinga.com/quote/SUPN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Gregory Fraser downgraded ANI Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) from Buy to Hold and slashed the price target from $80 to $60. ANI Pharmaceuticals shares fell 5.1% to close at $55.48 on Tuesday. <a href="https://www.benzinga.com/quote/ANIP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NVS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="537" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-1024x537.png" alt="" class="wp-image-542353" style="width:625px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-1024x537.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88.png 1292w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:<a href="https://www.benzinga.com/news/24/09/40792510/jim-cramer-says-aes-is-very-inexpensive-recommends-buying-this-industrial-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40792510/jim-cramer-says-aes-is-very-inexpensive-recommends-buying-this-industrial-stock">Jim Cramer Says AES Is &#8216;Very Inexpensive&#8217;, Recommends Buying This Industrial Stock</a></li>
</ul>

Jones Trading analyst Soumit Roy maintains Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Buy and lowers the price target from $6 to $4.

Jones Trading Maintains Buy on Adicet Bio, Lowers Price Target to $4

Canaccord Genuity analyst John Newman maintains Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Buy and lowers the price target from $19 to $8.

Canaccord Genuity Maintains Buy on Adicet Bio, Lowers Price Target to $8

HC Wainwright &amp; Co. analyst Edward White downgrades Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Buy to Neutral.

HC Wainwright & Co. Downgrades Adicet Bio to Neutral

On September 10, 2024, Adicet Bio, Inc. (the Company or Adicet) announced a strategic prioritization to focus ADI-001 development resources on autoimmune indications. The Company is focusing on advancing the clinical development of ADI-001 in four autoimmune indications, which include lupus nephritis, systemic lupus erythematosus, systemic sclerosis and anti-neutrophil cytoplasmic autoantibody associated vasculitis, and expects to further expand ADI-001 clinical development into additional autoimmune indications in the near term. Due to this prioritization, patient enrollment in the Phase 1 clinical study of ADI-001 in mantle cell lymphoma (MCL) has been closed, and topline results are reported below.
Across all doses, 10 evaluable patients with MCL that were treated with ADI-001 demonstrated an overall response rate (ORR) of 80% (8/10), a complete response (CR) rate of 60% (6/10), with a median duration of complete response of 17.5 months as of August 22, 2024. Patients were heavily pretreated with a median of 3 prior lines of therapy and 30% of patients had progressed on prior CAR T. In the Phase 1 study, ADI-001 demonstrated a favorable safety and tolerability profile, with no occurrences of graft-versus-host disease and low incidence of grade ≥3 cytokine release syndrome and neurotoxicity that compared favorably to data reported for autologous CD19 CAR T in MCL. Additional translational data from patients enrolled in the Phase 1 clinical study in relapsed/refractory B-cell non-Hodgkin's Lymphoma, which further support the significant potential of ADI-001 in autoimmune indications, will be presented during the 9th Annual CAR-TCR Summit on September 19, 2024 in Boston, MA.

Adicet Bio Shifts Focus to Autoimmune Diseases, Closes Lymphoma Trial for ADI-001

HC Wainwright &amp; Co. analyst Edward White reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Buy and maintains $10 price target.

HC Wainwright & Co. Reiterates Buy on Adicet Bio, Maintains $10 Price Target

Canaccord Genuity analyst John Newman maintains Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Buy and maintains $19 price target.

Canaccord Genuity Maintains Buy on Adicet Bio, Maintains $19 Price Target

Earnings

Adicet Bio Q2 2024 GAAP EPS $(0.33) Beats $(0.36) Estimate, Cash And Cash Equivalents Were $224.1M Will Be Sufficient To Fund Its Operating Expenses Into The Second Half Of 2026

WIIM

Adicet Bio shares are trading higher after the company announced that the FDA granted it Fast Track Designation to ADI-270 for the potential treatment of patients with metastatic/advanced clear cell renal cell carcinoma.

The FDA Has Granted Fast Track Designation To Adicet Bio's ADI-270 For Metastatic/Advanced Clear Cell Renal Cell Carcinoma Patients Who Have Been Treated With An Immune Checkpoint Inhibitor And A Vascular Endothelial Growth Factor Inhibitor

Adicet Bio Announces FDA Clearance Of Its IND Application For ADI-270 In Renal Cell Carcinoma

Adicet Bio shares are trading higher after the company was granted FDA Fast Track Designation to ADI-001 in lupus nephritis.

Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

Adicet Bio Says FDA Has Granted Fast Track Designation To ADI-001 For Potential Treatment Of Relapsed/Refractory Class III Or Class IV Lupus Nephritis

Analyst Soumit Roy from JonesTrading reiterated a Buy rating on Adicet Bio (ACET – Research Report) and decreased the price target to $4.00 from $6...

Buy Rating for Adicet Bio Backed by Strong Cell Therapy Potential and Upcoming Data Releases

Adicet Bio (ACET – Research Report) received a Hold rating and price target from H.C. Wainwright analyst Edward White today. The company's shares c...

Adicet Bio (ACET) was downgraded to a Hold Rating at H.C. Wainwright

In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on Adicet Bio (ACET – Research Report), with a price target of $6.00...

Buy Rating Affirmed: Adicet Bio's Strategic Pivot to Autoimmune Diseases and Solid Tumor Program Promise

Adicet Bio narrows focus on lead asset

Adicet Bio narrows focus on lead asset (update)

Adicet Bio ( ($ACET) ) has provided an announcement. Adicet Bio's recent press release on September 19, 2024, about their Phase 1 GLEAN trial resul...

Adicet Bio's GLEAN Trial Shows Promise in Autoimmune Therapy

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teva Pharmaceutical (TEVA – Research Report) and A...

Analysts Conflicted on These Healthcare Names: Teva Pharmaceutical (TEVA) and Adicet Bio (ACET)

JonesTrading analyst Soumit Roy has maintained their bullish stance on ACET stock, giving a Buy rating on September 11. Soumit Roy has given his Bu...

Buy Rating on Adicet Bio: Promising Phase 1 GLEAN Study Results and Therapeutic Potential in NHL

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on Adicet Bio (ACET – Research Report). The associated price target remai...

Adicet Bio's ADI-001 Shows Promising Efficacy in B-cell Malignancies: Maintaining Buy Rating with a $8 Price Target

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Adicet Bio (ACET – Research Report). The company's ...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Adicet Bio

News

Latest news for Adicet Bio (NASDAQ:ACET) Stock

People Also Watch